Move Doubles Capacity for iPSC Lines

By relocating its operations for production of human pluripotent stem cells (iPSCs) for drug discovery to a new base near Edinburgh, Roslin Cell Sciences returns to the site where parent company Roslin Cells Ltd was founded in 2006. The subsidiary will occupy a number of laboratories specially adapted for generation, expansion and testing of human iPSCs. The move which complements the company’s existing facilities in Cambridge, has doubled the company’s capacity for creating large numbers of iPSC lines from various cohorts of donors in support of commercial and academic drug research. 

John Mackenzie, CEO of Roslin BioCentre stated: “I am delighted to welcome our latest new tenant Roslin Cell Sciences to our burgeoning community at Roslin BioCentre. With their 19 new staff, they will add an extra and exciting dynamic to the building. Roslin Cell Sciences have been a pleasure to work with thus far and we very much look forward to future collaboration with them and indeed to their future success”. 

Aidan Courtney, CEO of Roslin Cell Sciences said “Moving back to the BioCentre provides Roslin Cell Sciences with the facilities and support it needs to deliver on expanding our capacity and extending our capabilities in stem cell processing.  As the demand for induced pluripotent stem cell derived models of disease to support the development of new drugs increases, we will be extremely well placed to ensure its customers get the full package of services they require.”